These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
106 related items for PubMed ID: 2494007
1. Recombinant tissue-type plasminogen activator in canine embolic pulmonary hypertension. Effects of bolus versus short-term administration on dynamics of thrombolysis and on pulmonary vascular pressure-flow characteristics. Prewitt RM, Shiffman F, Greenberg D, Cook R, Ducas J. Circulation; 1989 Apr; 79(4):929-38. PubMed ID: 2494007 [Abstract] [Full Text] [Related]
7. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Levine M, Hirsh J, Weitz J, Cruickshank M, Neemeh J, Turpie AG, Gent M. Chest; 1990 Dec; 98(6):1473-9. PubMed ID: 2123152 [Abstract] [Full Text] [Related]
8. Optimizing coronary thrombolysis with i.v. administration of recombinant tissue plasminogen activator. Single bolus vs double bolus vs front-loading. Prewitt RM, Schick U, Ducas J. Chest; 1996 Feb; 109(2):510-5. PubMed ID: 8620730 [Abstract] [Full Text] [Related]
13. Effects of recombinant tissue-type plasminogen activator on life-threatening acute pulmonary thromboembolism in a canine model: a comparative study of e6010 and alteplase. Tagami H, Utoh J, Sun LB, Okamoto K, Moriyama S, Kunitomo R, Kitamura N. Ann Thorac Cardiovasc Surg; 2000 Oct; 6(5):299-303. PubMed ID: 11173335 [Abstract] [Full Text] [Related]
18. A new short infusion dosage regimen of recombinant tissue plasminogen activator in patients with venous thromboembolic disease. Levine MN, Weitz J, Turpie AG, Andrew M, Cruickshank M, Hirsh J. Chest; 1990 Apr; 97(4 Suppl):168S-171S. PubMed ID: 2108854 [Abstract] [Full Text] [Related]